Last reviewed · How we verify

dexamethasone to injury site

Henry Ford Health System · Phase 3 active Small molecule

Dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting the production of pro-inflammatory cytokines.

Dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting the production of pro-inflammatory cytokines. Used for Treatment of acute injuries.

At a glance

Generic namedexamethasone to injury site
SponsorHenry Ford Health System
Drug classCorticosteroid
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Dexamethasone works by binding to glucocorticoid receptors, which then translocate to the nucleus and inhibit the transcription of pro-inflammatory genes. This leads to a decrease in the production of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, resulting in reduced inflammation and immune suppression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: